Overview
ELV market data
Price History
ELV price chart · 1M
- O
- 398.59
- H
- 404.98
- L
- 394.69
- C
- 396.29
- Vol
- 86,125.00
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $398.59
- Previous Close
- $398.19
- Day High
- $404.98
- Day Low
- $394.69
- 52 Week High
- $431.76
- 52 Week Low
- $362.61
- 7 Day Return
- -3.56%
- 30 Day Return
- -1.13%
- 90 Day Return
- +2.60%
- 1 Year Return
- +1.49%
- Daily Notional Volume
- $34.1M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 17.47 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $25.21 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.65 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 1.2% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 2.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $274.84 – $436.24 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $86.7B · P/B 1.78 · P/S 0.43.
Company News
10 captured
The American Journal of Managed Care® announces Aaron L. Schwartz, M.D., Ph.D., as 2026 Emerging Leader in Managed Care Research Award recipientGlobenewswire Inc ·
How Centene's Strong Cash Flow Is Reshaping Its Balance SheetZacks Investment Research ·
Here's How CVS' Health Services Arm Is Positioned for Long-Term GrowthZacks Investment Research ·
Can Centene's Medicare Advantage Strategy Unlock Better Margins?Zacks Investment Research ·